Message from CEO
Our innovation drives a movement toward a future where brain disorders are measurable, manageable, and treatable —empowering patients and families to lead fuller lives, which is the core of our vision.
Building a deeper understanding of brain disease through biological insight and scientific collaboration.
Brain disorders remain among the most complex challenges in medicine.
Advances in biomarker science, computational biology, and neuroscience are redefining what is possible.
At Circular Genomics, we believe a deeper understanding of disease biology is essential to advancing precision neurology. Through circular RNA, we are helping shape a future of earlier biological insight, more precise interventions, and improved outcomes for people affected by neurological disease.
Understanding the complex biological processes that drive neurological disease.
Stable molecular signals providing visibility into multiple interconnected biological pathways.
A proprietary platform that translates circRNA signals into actionable biological insights.
Research tools designed to support biomarker discovery, patient stratification, therapeutic development, and precision neurology.
Our innovation drives a movement toward a future where brain disorders are measurable, manageable, and treatable —empowering patients and families to lead fuller lives, which is the core of our vision.
Circular Genomics was founded on a breakthrough discovery: the direct link between disease and a new class of brain-derived circular RNA biomarkers. This seminal finding isn't just our origin story; it's the cornerstone of our mission to revolutionize the future of neurological and psychiatric treatment with cutting-edge biomarkers for personalized care.
Moving beyond today's diagnostic barriers, we harness the power of brain-derived circular RNA biomarkers, providing clinicians with a real-time view of brain disease via simple blood tests. This means more accurate detection of the disease pathology, leading to potentially faster and more informed treatment selection decisions for several neurological and psychiatric conditions. Our innovation drives a movement toward a future where brain disorders are measurable, manageable, and treatable—empowering patients and families to lead fuller lives, which is the core of our vision.
Our team is passionate and already making a difference for patients and providers. As shown in clinical studies, MindLight, our first commercially available circular RNA biomarker diagnostic, predicts SSRI response in patients suffering from major depressive disorder (MDD) with a diagnostic accuracy of close to 80%. We are actively developing
he Circular Genomics team brings together expertise across neuroscience, genomics, diagnostics, clinical research, and biotechnology commercialization.
We’re building a team of scientists, innovators, and industry leaders committed to transforming biological signals into molecular intelligence.
